Aditxt to acquire Appili Therapeutics, Inc. with a closing target of September 30
Acquiring Company
Aditxt
Acquired Company
Appili Therapeutics Inc.
Richmond
HalifaxBiotechnologyHealth CareBiotechnologyHealth CareScience And EngineeringDescription
Aditxt, Inc. (“Aditxt”) has signed a second Amending Agreement with Appili Therapeutics Inc. (“Appili”), targeting the acquisition of all issued and outstanding Class A common shares of Appili through a court-approved plan of arrangement governed by the Canada Business Corporations Act. The transaction is conditional upon Aditxt raising at least US$20 million in financing before closing and subject to other customary conditions, including the receipt of all necessary court, regulatory, and stock exchange approvals.
Quick answer
Aditxt is acquiring Appili Therapeutics Inc., announced July 25, 2024. Aditxt is based in Richmond, Virginia, United States.
- Who acquired Appili Therapeutics Inc?
- Aditxt agreed to acquire Appili Therapeutics Inc. on July 25, 2024.
- How much did Aditxt pay for Appili Therapeutics Inc?
- The deal value was not disclosed.
- What does Aditxt do?
- Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming.
- Where are Aditxt and Appili Therapeutics Inc. based?
- Aditxt is based in Richmond, Virginia, United States. Appili Therapeutics Inc. is based in Halifax, England, United Kingdom.
- Who are the decision-makers at Aditxt?
- Fundz holds 1 contact at Aditxt. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Science And Engineering and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- P95 completes acquisition of Assign DMB, expanding data management and biostatistics services (September 5, 2024)
- ADVI Health completes acquisition of Partnership for Health Analytic Research to enhance Strategic Analytics, Value and Economics capabilities (August 23, 2024)
- KARL STORZ completes acquisition of Asensus Surgical, Inc. to strengthen its position in robotic and digital surgical market (August 22, 2024)
- Leapcure Acquires Honeybee Trials: Enhancing Patient Engagement and Research Site Solutions (August 13, 2024)
- Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical (August 9, 2024)
- SurgNet Health Partners, Inc. completes acquisition of Tuscaloosa Endoscopy Center to advance care and patient experience (August 8, 2024)
Who to call at Aditxt, and when
When Aditxt changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Aditxt raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aditxt, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aditxt. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aditxt makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Appili Therapeutics Inc.?
Appili Therapeutics Inc. was acquired by Aditxt, based in Richmond. The deal was reported on July 25, 2024. Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt is privately held and operates in Biotechnology.
When did Aditxt acquire Appili Therapeutics Inc.?
Aditxt's acquisition of Appili Therapeutics Inc. was reported on July 25, 2024. Aditxt, Inc. (“Aditxt”) has signed a second Amending Agreement with Appili Therapeutics Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Appili Therapeutics Inc. do?
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. It is privately held, operating in Biotechnology, and is based in Halifax.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.